William Blair Predicts Amedisys' Q2 Earnings (NASDAQ:AMED)

Amedisys, Inc. (NASDAQ:AMED - Free Report) - Research analysts at William Blair cut their Q2 2025 earnings per share (EPS) estimates for Amedisys in a research note issued on Thursday, April 24th. William Blair analyst M. Larew now expects that the health services provider will post earnings of $1.32 per share for the quarter, down from their previous forecast of $1.33. The consensus estimate for Amedisys' current full-year earnings is $4.40 per share.

Amedisys (NASDAQ:AMED - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The health services provider reported $1.25 EPS for the quarter, topping the consensus estimate of $1.13 by $0.12. The company had revenue of $594.78 million for the quarter, compared to analyst estimates of $597.43 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The firm's revenue was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.03 earnings per share.

A number of other research analysts have also issued reports on AMED. Royal Bank of Canada reissued an "outperform" rating and issued a $100.00 target price on shares of Amedisys in a report on Wednesday, April 16th. Stephens reissued an "equal weight" rating and issued a $101.00 target price on shares of Amedisys in a report on Tuesday, March 4th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $100.75.

Amedisys Stock Performance

AMED traded up $0.17 during trading on Friday, hitting $94.89. 87,214 shares of the stock were exchanged, compared to its average volume of 405,867. The firm has a market capitalization of $3.11 billion, a P/E ratio of 37.65, a PEG ratio of 1.78 and a beta of 0.89. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05. The stock has a fifty day moving average price of $92.32 and a two-hundred day moving average price of $91.76. Amedisys has a 1-year low of $82.15 and a 1-year high of $98.95.

Institutional Trading of Amedisys

Institutional investors have recently modified their holdings of the business. Trexquant Investment LP boosted its stake in shares of Amedisys by 1,317.8% in the fourth quarter. Trexquant Investment LP now owns 87,719 shares of the health services provider's stock valued at $7,964,000 after buying an additional 81,532 shares in the last quarter. ABC Arbitrage SA purchased a new stake in Amedisys during the fourth quarter worth $2,522,000. Oddo BHF Asset Management Sas purchased a new stake in Amedisys during the third quarter worth $7,238,000. Empowered Funds LLC purchased a new stake in Amedisys during the fourth quarter worth $318,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in Amedisys during the fourth quarter worth $590,000. 94.36% of the stock is currently owned by hedge funds and other institutional investors.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.